Production of human monoclonal antibodies specific for hepatitis B surface antigen

• US 5,565,354 A
• Filed: 06/14/1994
• Issued: 10/15/1996
• Est. Priority Date: 09/05/1986
• Status: Expired due to Term

• Current Assignee: Sandoz Inc. (Novartis Ag)
• Original Assignee: Sandoz Inc. (Novartis Ag)
• Inventors: Ostberg, Lars G.
• Primary Examiner(s): Hutzell, Paula K.
• Assistant Examiner(s): EBERT, RAY
• Application Number:
  US08/259,372
• Time in Patent Office: 854 Days
• Field of Search: 530/388.15, 530/388.3, 435/70.21, 435/240.27, 935/99, 935/100, 424/149.1
• US Class Current: 435/339
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 16/082 Hepadnaviridae, e.g. hepatitis B virus

Abstract

Monoclonal antibodies effective for the diagnosis and treatment of diseases caused by infection with hepatitis B have been prepared from a cell line obtained by fusing a xenogeneic hybridoma designated SPAZ 4 with blood cells of a patient immunized with hepatitis B vaccine. The invention also provides cocktails of the above monoclonal antibodies specific for different epitopes of hepatitis B surface antigen.

Claims

1. A cell line designated ATCC HB 9234.

2. A human monoclonal antibody produced by the cell line designated ATCC HB 9234.

3. A Fab fragment of the human monoclonal antibody of claim 2.

7. A composition comprising the antibody of claim 2 and a vehicle.

4. A human monoclonal antibody comprising a heavy chain variable region having the amino acid sequence shown in Table 8-1 (SEQ ID NO:

2) and a light chain variable region having the amino acid sequence shown in Table 9-1 (SEQ ID NO;

10).

5. A cell line producing the antibody of claim 4.

6. A Fab fragment of the antibody of claim 4.

8. A composition comprising the antibody of claim 4 and a vehicle.

9. The human monoclonal antibody of claim 4, wherein the heavy chain variable region is encoded by the DNA sequence shown in Table 8-1 (SEQ ID NO:

1) and the light chain variable domain is encoded by the DNA sequence shown in Table 9-1 (SEQ ID NO;

9).